|
Canada-0-LABORATORIES 公司名錄
|
公司新聞:
- Nonstatin Cholesterol Medications - NEXLIZET® NEXLETOL®
NEXLIZET is a combination of 2 medicines, bempedoic acid and ezetimibe The bempedoic acid portion of NEXLIZET was studied in a large clinical trial on reducing heart attack and heart procedures, like stent placement or bypass surgery, in adults who were unable to take recommended statin treatment
- NEXLIZET® NEXLETOL® HCP Information - Official Site
The most common adverse reactions in the cardiovascular outcomes trial for bempedoic acid, a component of NEXLIZET and NEXLETOL, at an incidence of ≥2% and 0 5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis
- U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . .
U S FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
- U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . .
ANN ARBOR, Mich , March 22, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded
- NEXLIZET® to Prevent Heart Attacks and Cardiovascular . . .
Esperion announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary prevention patients
- FDA Expands Labels for Nexletol, Nexlizet to Prevent Heart . . .
U S FDA approves broad new labels for Nexletol and Nexlizet to prevent heart attacks and cardiovascular procedures in both primary and secondary prevention patients, regardless of statin use
- NEXLIZET® Clinical Trial Results - See How It Performed
How can NEXLIZET help you? If you have been told by your doctor you are at risk for a major heart event and you are unable to take recommended statin treatment, NEXLIZET can help lower your risk of heart attack and heart procedures, like stent placement or bypass surgery
- Nexlizet: Dosage, side effects, uses, interactions, cost, and . . .
Dosage for reducing certain cardiovascular risks Nexlizet is approved to help reduce the risk of heart attack and coronary revascularization (a type of heart procedure) in certain adults
- FDA Approves Esperions NEXLETOL NEXLIZET for Wider Heart . . .
Esperion (NASDAQ: ESPR) has received FDA approval for expanded labels for NEXLETOL® and NEXLIZET® tablets, allowing access to over 70 million patients in the U S The new labels include indications for cardiovascular risk reduction and LDL-C lowering in both primary and secondary prevention patients, with or without statins The company also received a positive CHMP opinion in Europe, with a
- U. S. FDA Approves Broad New Labels for Esperion . . . - BioSpace
U S FDA approves broad new labels for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets to prevent heart attacks and cardiovascular procedures in both primary and secondary prevention patients, regardless of statin use
|
|